GMEDGlobus Medical, Inc.

$74.65+34% 1Y

Is the business good?

Mixed

The checks split: 8 of 9 health tests passed and earnings fully cash-backed (1.8×), but margins compressing.

2 good, 1 to watch, 1 neutral
Fundamental health (F-score)8 / 9SEC EDGAR · Dec 31, 2025

High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.75×derived · Jun 30, 2026

Operating profit is fully backed by cash. Conversion is worsening vs a year ago.

Margin direction, 3 years−1.3 pts

Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.

Where ROE comes from10% ROA

Margin-driven, fat margins on slower asset turns. ROE 11% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionbetter than 70% of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is GMED?

Globus Medical, Inc. earns 12% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.

12%

Return on invested capital · cost of capital 9.0% · 3.1 points above what the capital costs: growth creates value

Operating margin
20%

Operating margin · Medical Devices median 2.1% · 12 months to Q2 2026

Cash conversion
1.75×

Cash conversion · 2.49× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
+0.65%

Share count, year on year · flat: no meaningful dilution

Operating margin by fiscal year
YearOperating margin
FY202014%
FY202118%
FY202222%
FY20238.5%
FY20246.6%
FY202516%
Details›
Gross margin12 months to Q2 2026
69%
Operating margin12 months to Q2 2026
20%
Net margin12 months to Q2 2026
17%
Free cash flow margin
24%
R&D as % of revenue
4.7%
Revenue, trailing twelve months
$3.14B
Free cash flow, trailing twelve months
$756M
Net income, trailing twelve months
$535M
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
12%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.